Brief Summary
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cureno evidence of disease; complete cancer remission at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cellsthe basic structural and functional unit of all living things after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.
Intervention / Treatment
- Drug: Cilta-cel
- Drug: Talquetamab
- Drug: Daratumumab
- Drug: Teclistamab
- Drug: Bortezomib
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Cyclophosphamide
- Drug: Fludarabine
Inclusion Criteria:
- Participants with documented new diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy
- Participants must have standard-risk MM (stage I and II) based on revised International Stagingthe process of determining how big the cancer is, where it started and if it has spread to other areas System (R-ISS)
- Participants must be considered fit (score equals to [=] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living)
- Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) (>=10 gram per liter [g/L] for institutions using alternative units) or urine M-protein level >= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status gradea description of how abnormal cancer cells and tissue look under a microscope when compared to healthy cells of 0 or 1.